Mukai, H., Kato, K., Esaki, T., Ohsumi, S., Hozomi, Y., Matsubara, N., . . . Nambu, Y. (2016). Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors. Invest New Drugs.
Citação norma ChicagoMukai, Hirofumi, et al. "Phase I Study of NK105, a Nanomicellar Paclitaxel Formulation, Administered On a Weekly Schedule in Patients With Solid Tumors." Invest New Drugs 2016.
MLA CitationMukai, Hirofumi, et al. "Phase I Study of NK105, a Nanomicellar Paclitaxel Formulation, Administered On a Weekly Schedule in Patients With Solid Tumors." Invest New Drugs 2016.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.